U.S. stock and bond markets are fairly valued, if not somewhat overvalued given the current macroeconomic backdrop, said Jim Sarni, managing principal at Payden & Rygel (PYCBX) . With that in mind, investors better watch out for a sharp drop in oil or a sudden downturn in economic growth. Sarni said more than one short-term interest rate hike in 2016 from the Federal Reserve will also hurt the market, although he regards this probability as low considering the worse-than-expected May jobs report. In his view, while the Fed may want to raise rates it seems as though the data keeps getting in the way. 'Notwithstanding Friday's employment figures, a case can still be reasonably made that higher short-term rates are warranted sometime in 2016 if for no other reason than to begin the interest rate normalization process as it seems clear to us that the U.S. economy no longer needs an emergency level policy,' said Sarni.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.